Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$4.75 +14.5%	$4.31	$3.35 ▼ $22.00	$122.89M	0.52	85,855 shs	67,719 shs
MGNX MacroGenics	$1.78 +22.8%	$1.45	$0.99 ▼ $5.77	$112.30M	1.65	754,526 shs	1.91 million shs
OCX OncoCyte	$2.97	$2.99	$1.92 ▼ $4.75	$84.94M	0.97	58,328 shs	49,466 shs
OTLC Oncotelic Therapeutics	$0.06 +5.4%	$0.06	$0.02 ▼ $0.07	$25.52M	-0.66	113,233 shs	5,100 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	+14.46%	+31.22%	+19.05%	-29.84%	-70.48%
MGNX MacroGenics	+22.76%	+29.83%	+19.87%	-21.59%	-63.75%
OCX OncoCyte	0.00%	-8.05%	+5.02%	-23.85%	+10.41%
OTLC Oncotelic Therapeutics	+5.40%	-3.85%	+6.11%	+56.25%	+68.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTNM Contineum Therapeutics	1.9066 of 5 stars	3.6	2.0	0.0	0.0	0.0	0.8	0.6
MGNX MacroGenics	3.6263 of 5 stars	3.2	1.0	0.0	4.4	1.4	2.5	0.6
OCX OncoCyte	1.9674 of 5 stars	3.4	4.0	0.0	0.0	0.6	0.8	0.6
OTLC Oncotelic Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTNM Contineum Therapeutics	3.20	Buy	$22.50	373.68% Upside
MGNX MacroGenics	2.40	Hold	$5.71	221.03% Upside
OCX OncoCyte	2.75	Moderate Buy	$6.06	104.12% Upside
OTLC Oncotelic Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest OTLC, CTNM, MGNX, and OCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	OCX OncoCyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/21/2025	OCX OncoCyte	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $8.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/19/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$25.00 ➝ $20.00
5/15/2025	CTNM Contineum Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $31.00
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00
5/13/2025	OCX OncoCyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.25 ➝ $4.25
4/8/2025	OCX OncoCyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.25 ➝ $4.25
3/28/2025	OCX OncoCyte	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
3/25/2025	MGNX MacroGenics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $2.00

(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTNM Contineum Therapeutics	$50M	2.46	$0.75 per share	6.35	($3.72) per share	-1.28
MGNX MacroGenics	$152.43M	0.74	N/A	N/A	$2.46 per share	0.72
OCX OncoCyte	$3.84M	22.10	N/A	N/A	$2.48 per share	1.20
OTLC Oncotelic Therapeutics	$70K	364.55	$0.02 per share	3.12	$0.03 per share	2.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTNM Contineum Therapeutics	$22.72M	-$1.97	N/A	N/A	N/A	N/A	-49.92%	-20.52%	8/12/2025 (Estimated)
MGNX MacroGenics	-$9.06M	-$0.89	N/A	N/A	N/A	-69.07%	-89.42%	-38.57%	8/5/2025 (Estimated)
OCX OncoCyte	-$27.78M	-$3.53	N/A	N/A	N/A	-6,122.29%	-269.32%	-59.71%	8/6/2025 (Estimated)
OTLC Oncotelic Therapeutics	-$7.90M	-$0.01	N/A	∞	N/A	N/A	-8.48%	-3.09%	N/A

Latest OTLC, CTNM, MGNX, and OCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
5/12/2025	Q1 2025	OCX OncoCyte	-$0.24	-$0.26	-$0.02	-$0.26	$0.13 million	$2.14 million
3/24/2025	Q4 2024	OCX OncoCyte	-$0.40	$0.48	+$0.88	-$1.93	$0.16 million	$1.49 million
3/20/2025	Q4 2024	MGNX MacroGenics	-$0.23	-$0.25	-$0.02	-$0.25	$34.17 million	$49.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
OCX OncoCyte	N/A	N/A	N/A	N/A	N/A
OTLC Oncotelic Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTNM Contineum Therapeutics	N/A	37.06	37.06
MGNX MacroGenics	N/A	3.75	3.69
OCX OncoCyte	N/A	0.53	0.50
OTLC Oncotelic Therapeutics	0.28	0.01	0.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTNM Contineum Therapeutics	N/A
MGNX MacroGenics	96.89%
OCX OncoCyte	55.35%
OTLC Oncotelic Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CTNM Contineum Therapeutics	11.30%
MGNX MacroGenics	13.00%
OCX OncoCyte	2.05%
OTLC Oncotelic Therapeutics	39.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTNM Contineum Therapeutics	31	25.87 million	N/A	N/A
MGNX MacroGenics	430	63.09 million	55.67 million	Optionable
OCX OncoCyte	120	28.60 million	17.18 million	No Data
OTLC Oncotelic Therapeutics	20	408.29 million	246.93 million	Not Optionable

OTLC, CTNM, MGNX, and OCX Headlines

Recent News About These Companies

Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm

April 22, 2025 | globenewswire.com

Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023

April 16, 2025 | globenewswire.com

Oncotelic Therapeutics Inc (OTLC)

April 10, 2025 | nasdaq.com

Oncotelic Therapeutics Delays Yearly Report Filing

March 31, 2025 | tipranks.com

Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI

March 31, 2025 | globenewswire.com

Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference

March 25, 2025 | globenewswire.com

Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon

February 25, 2025 | globenewswire.com

Oncotelic CEO Vuong Trieu to Present Groundbreaking Research on Transforming Growth Factor Beta 2 (TGFB2) at SWCR 2025 Conference

February 13, 2025 | globenewswire.com

Oncotelic Therapeutics Implements PDAOAI Platform

December 31, 2024 | globenewswire.com

ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024

November 6, 2024 | globenewswire.com

ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS

October 28, 2024 | finance.yahoo.com

ONCOTELIC PRESENTATION AT PRECISION IN DRUG DISCOVERY & PRECLINICAL SUMMIT SAN DIEGO 2024

October 24, 2024 | finance.yahoo.com

Russia faces new wave of drop in clinical trials for new drugs

September 30, 2024 | thepharmaletter.com

Alibaba rises on report it will charge software service fee

July 29, 2024 | uk.finance.yahoo.com

Product Manager Scott Myers to Present at 2nd Global Summit on Artificial Intelligence

July 29, 2024 | globenewswire.com

ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY

June 11, 2024 | globenewswire.com

ONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETING

May 30, 2024 | globenewswire.com

ONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETING

May 20, 2024 | globenewswire.com

Oncotelic Therapeutics Inc OTLC

May 19, 2024 | morningstar.com

ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024

May 16, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLC, CTNM, MGNX, and OCX Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

$4.75 +0.60 (+14.46%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$4.76 +0.01 (+0.21%)

As of 06/6/2025 04:19 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

MacroGenics NASDAQ:MGNX

$1.78 +0.33 (+22.76%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$1.72 -0.06 (-3.37%)

As of 06/6/2025 07:34 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

OncoCyte NASDAQ:OCX

$2.97 0.00 (0.00%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$2.95 -0.02 (-0.67%)

As of 06/6/2025 06:16 PM Eastern

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Oncotelic Therapeutics OTCMKTS:OTLC

$0.06 +0.00 (+5.40%)

As of 06/6/2025 03:29 PM Eastern

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time